21132-76-3

Usage

Purification Methods

If the IR shows OH bands, then it should be dissolved in oxalyl chloride in *C6H6 solution and warmed at 35o for 24hours in the absence of moisture, evaporated and distilled in a vacuum of 10-5mm. It is soluble in *C6H6 and Et2O. It is moisture sensitive and is LACHRYMATORY. [Francis et al. J Chem Soc 1001 1937, Levene & Taylor J Biol Chem 59 905 1924, Beilstein 2 III 1076.]

InChI:InChI=1/C22H43ClO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h2-21H2,1H3

Upstream product

• 79-37-8 oxalyl dichloride 
• 112-85-6 n-docosanoic acid 

Downstream Products

• 82052-48-0 docosananilide 
• 5667-66-3 docosanophenone 
• 79551-07-8 Docosanoic acid 1-[4-((E)-7-ethoxy-3,7-dimethyl-oct-2-enyloxy)-phenyl]-propyl ester 
• 61682-74-4 1,2-propanediol dibehenoate 
• 3061-75-4 Docosanylamide 
• 154413-75-9 4-Docosanoylamino-benzoic acid methyl ester 
• 855835-52-8 2-docosanoyloxy-1,3-bis-palmitoyloxy-propane 
• 6938-67-6 1,20-bis-cyclohexyloxy-eicosane 
• 412031-53-9 Acetic acid (2R,3R,4R,6S)-4-acetoxy-2-acetoxymethyl-6-((2S,3S,4R)-3,4-bis-benzyloxy-2-docosanoylamino-octadecyloxy)-tetrahydro-pyran-3-yl ester 
• 243474-09-1 Docosanoic acid ((S)-2-benzyloxy-1-tetradecylcarbamoyl-ethyl)-amide 
• 676999-85-2 (2S,3S,4R)-2-docosanoylamino-3,4-di-O-benzyl-1-O-(2-O-methyl-3,4,6-tri-O-benzyl-α-D-galactopyranosyl)-1,3,4-octadecanetriol 
• 866030-97-9 (2S,3S,4R)-3,4-di-O-benzyl-2-docosanoylamino-1-O-(3,4,6-tri-O-benzyl-2-deoxy-2-fluoro-α-D-galactopyranosyl)-1,3,4-octadecanetriol 
• 956038-77-0 (2S,3S,4R)-3-benzyloxy-2-docosanoylamino-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)octadec-5-yn-4-ol 
• 956038-78-1 (2S,3S,4R)-3-benzyloxy-2-docosanoylamino-8-methyl-1-(2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyloxy)non-5-yn-4-ol 

Relevant academic research and scientific papers

Mixed Monolayers for the Design of Structured Surfaces To Induce Oriented 3-D Crystallization

Mixed monolayers containing two different amphiphiles C19H39CONHCH2CH2CO2H(A) and C19H39CONH2(B) were designed in order to form a two-dimensional (2-D) crystalline solid solution in which the A-type molecules form domains within the sea of B-type molecules.A "continuous" 2-D arrangement of the aliphatic chains was expected, driven by the amide hydrogen bonding requirement; a tendency for the formation of the embeded A-type domains should be provided by the interactions between the -CH2CH2CO2H head group moieties.The mixed monolayers served to promote the oriented nucleation of silver propionate 3-D crystals attached at the monolayer-solution interface.Only the A-type domains induced silver propionate crystallization whereas the B-type domains were essentially inert.The mixed A + B monolayers were found to be efficient nucleators down to a 1:10 molar ratio, providing proof for the existence of A-type domains.Additional information such as the structure and ion-binding properties of the mixed monolayers was furnished by specular X-ray reflectivity and grazing incidence X-ray diffraction using synchrotron radiation.

Catalyst for synthesizing acyl chloride compounds and application thereof

The invention relates to a catalyst for synthesizing an acyl chloride compound and application of the catalyst. The structural formula is as shown in the specification, and in the formula, R is alkali of which the carbon atom number is 1-12. The catalyst is capable of effectively increasing the product yield, improving the production efficiency and lowering the production cost of acyl chloride, and has wide application prospects. The invention further provides a method for synthesizing acyl chloride with the catalyst.

ANTIVIRAL PRODRUGS AND NANOFORMULATIONS THEREOF

The present invention provides prodrugs and methods of use thereof.

Synthesis of New Lipophilic Cyclopentafullerenes from Long-Chain Alka-2,3-dienoates

Abstract: Long-chain alka-2,3-dienoates were synthesized via the Wittig reaction fromthe corresponding fatty acids, and the subsequent triphenylphosphine-catalyzed[3+2]-cycloaddition to fullerene C60 afforded newlipophilic cyclopentafullerenes.

Synthesis of glycerolipids containing simple linear acyl chains or aromatic rings and evaluation of their Mincle signaling activity

Mincle, expressed in activated phagocytes, recognizes the lipid ligand to activate the innate immune system. We have synthesized glycerol derivatives possessing simple alkyl chains or aromatic rings and elucidated their structure-activity relationships us

SUGAR FATTY ACID ESTER AND OIL GELLING AGENT

PROBLEM TO BE SOLVED: To provide a compound that can gel various oils. SOLUTION: The present invention provides a compound containing 1,5-anhydro-D-glucitol fatty acid ester, represented by formula (1), or 1,5-anhydro-D-mannitol fatty acid ester, and a gelling agent containing the compound. (R1 independently represent an acyl group derived from a C10, 11 or 13-22 linear saturated fatty acid). SELECTED DRAWING: None COPYRIGHT: (C)2019,JPOandINPIT

Discovery of Hydrolysis-Resistant Isoindoline N -Acyl Amino Acid Analogues that Stimulate Mitochondrial Respiration

N-Acyl amino acids directly bind mitochondria and function as endogenous uncouplers of UCP1-independent respiration. We found that administration of N-acyl amino acids to mice improves glucose homeostasis and increases energy expenditure, indicating that this pathway might be useful for treating obesity and associated disorders. We report the full account of the synthesis and mitochondrial uncoupling bioactivity of lipidated N-acyl amino acids and their unnatural analogues. Unsaturated fatty acid chains of medium length and neutral amino acid head groups are required for optimal uncoupling activity on mammalian cells. A class of unnatural N-acyl amino acid analogues, characterized by isoindoline-1-carboxylate head groups (37), were resistant to enzymatic degradation by PM20D1 and maintained uncoupling bioactivity in cells and in mice.

Alkyl chain elongation and acyl group effects in a series of Eu/Tb complexes with hexadentate π-electronic skeletons and their enhanced luminescence in solutions

Five Eu complexes with long alkyl chain groups, abbreviated as EuLCx ("x" indicates the number of methylene groups: x = 8, 12, 14, 18, and 22), were synthesized to evaluate their structural and luminescence properties in chloroform. The mother helicate Eu complex, EuL, which has two bipyridine moieties bridged by an ethylenediamine, has been previously reported. A reduced form in which the azomethine groups of L also coordinated to the Eu ion, EuLH, was newly prepared. EuLH also adopts a helicate molecular structure based on single crystal X-ray structural analysis. The amine hydrogens of the bridging ethylenediamine of LH are active sites for substitution and were exchanged with five different alkyl chains to form EuLCx. Luminescence band positions and shapes of EuLCx in chloroform were completely identical, with a quantum yield of 37.1 ± 1.2 and a lifetime of around 1.25 ms. This indicates that the environments surrounding the Eu ion in the various complexes are all similar. Luminescence quantum yields of TbLH and TbLC18 are also strengthened, 48.7% in acetonitrile and 55% in chloroform, respectively. Potential energy surfaces were also described by using density functional theory, suggesting the possibility of a 1:2 complex of Eu and the ligand as a main luminescent species in solutions. This 1:2 complexation forms Eu-oxygen coordination using acyl groups. It indicates that the acyl group modification results in a different structure from the mother complexes.

IMMUNOSTIMULATING AGENT

The present invention aims to provide an immunostimulating agent superior in an immunostimulatory effect, particularly a compound useful as a vaccine adjuvant, a pharmaceutical composition containing the compound, a vaccine containing the compound and an antigen. An immunostimulating agent containing at least one kind of a compound represented by the formula (I): wherein each symbol is as defined in the present specification, or a salt thereof.

IMMUNOSTIMULATING AGENT

The present invention aims to provide an immunostimulating agent superior in an immunostimulatory effect, particularly a compound useful as a vaccine adjuvant, a pharmaceutical composition containing the compound, a vaccine containing the compound and an